GLP-1 Pipeline 2026: Every New Obesity Drug in Development

The obesity drug market is about to get very crowded. After years of Novo Nordisk and Eli Lilly dominating the landscape, a wave of new competitors is approaching—from triple agonists that could lose 30% of body weight to monthly injections that eliminate the weekly routine, to muscle-sparing formulations that address the biggest concern patients have about weight loss drugs.

For patients currently using GLP-1 medications, this pipeline represents more choice, better efficacy, and—critically—lower prices driven by competition. Here’s every significant drug in the pipeline, organized by how soon you might actually be able to use it.

Tier 1: FDA Decision Expected 2026

Orforglipron (Eli Lilly) — Oral GLP-1

Eli Lilly’s oral small-molecule GLP-1 has already been submitted to the FDA, with a decision expected by May 2026. Unlike the Wegovy pill, orforglipron can be taken without food or water restrictions—a significant convenience advantage. The ATTAIN trials showed 11–12.4% weight loss, and it also beat AstraZeneca’s Farxiga and Novo’s semaglutide in head-to-head diabetes trials. Truist Securities estimates that Lilly’s trio of Mounjaro, Zepbound, and orforglipron could reach $101 billion in peak sales worldwide.

CagriSema (Novo Nordisk) — Combination Injection

CagriSema combines semaglutide with cagrilintide, an amylin analog. Novo Nordisk filed the NDA in December 2025. The REDEFINE 1 trial showed 22.7% weight loss at 68 weeks—significantly more than semaglutide alone. REDEFINE 4 is a head-to-head trial against tirzepatide, which could determine market positioning. FDA decision is expected in 2026 or early 2027.

Tier 2: Phase 3 Data Coming in 2026, Possible Approval 2027–2028

Retatrutide (Eli Lilly) — Triple Agonist

The highest-efficacy obesity drug ever tested. TRIUMPH-4 showed 28.7% weight loss at 68 weeks. Seven additional Phase 3 trials report in 2026, covering obesity, diabetes, sleep apnea, MASH, and cardiovascular outcomes. TRANSCEND-T2D-1 already showed 2.0% HbA1c reduction and 17% weight loss at 40 weeks. Expected approval: late 2027 or early 2028. Projected sales: $15.6 billion by 2031.

Amycretin (Novo Nordisk) — GLP-1/Amylin Agonist

Novo’s next-generation candidate showed up to 25.4% weight loss at just 36 weeks in Phase 2—and critically, showed no signs of plateau. Available in both oral and injectable formulations. Phase 3 began Q1 2026. If successful, it could outperform CagriSema and position Novo against Lilly’s retatrutide.

PF’3944 (Pfizer/Metsera) — Monthly GLP-1 Injection

Pfizer’s monthly injectable GLP-1, acquired through its $10 billion purchase of Metsera, showed 12.3% placebo-adjusted weight loss at 28 weeks in the VESPER-3 Phase 2b trial, with no plateau observed. Ten Phase 3 trials are planned for 2026. Modeling suggests a higher monthly dose could reach 16% weight loss. The monthly dosing frequency is the key differentiator—one injection per month instead of four.

Survodutide (Boehringer Ingelheim/Zealand) — Dual GLP-1/Glucagon Agonist

This dual agonist is primarily being developed for MASH (metabolic liver disease) but showed 19% weight loss in Phase 2 for obesity. The Phase 3 SYNCHRONIZE program results are expected late 2026. Potential FDA approval as early as 2027, with the liver disease indication providing an additional insurance coverage pathway.

VK2735 (Viking Therapeutics) — Dual GLP-1/GIP Agonist

The small biotech that’s taking on the pharma giants. Phase 2 showed 14.7% weight loss in just 13 weeks—with no plateau. The pivotal VANQUISH-1 Phase 3 trial enrolled 4,650 participants, with results expected in 2026. Viking’s lean structure means they could price aggressively if approved, putting downward pressure on the entire market.

Tier 3: Phase 2–3, Potential Approval 2028+

Aleniglipron (Structure Therapeutics) — Oral Small Molecule

Showed 15.3% weight loss in Phase 2 at the highest dose. Phase 3 begins mid-2026. Another oral option that could add competitive pressure to the pill market alongside Wegovy pill and orforglipron.

CT-388 (Roche) — Weekly GLP-1/GIP Agonist

Roche’s dual agonist showed 22.5% weight loss in Phase 2 with less than 6% discontinuation—one of the best tolerability profiles in the class. The low discontinuation rate could be a major differentiator if maintained in Phase 3.

Bimagrumab + Semaglutide — Muscle-Preserving Combination

The Phase 2b BELIEVE trial showed 22.1% weight loss at 72 weeks, with 92.8% of weight lost coming from fat mass (versus the typical 55–70% with semaglutide alone). Eli Lilly acquired bimagrumab for up to $1.9 billion. A tirzepatide + bimagrumab trial is underway. This could address the “muscle loss” concern that is GLP-1 therapy’s biggest patient worry.

AstraZeneca’s Muscle-Sparing Approach

AstraZeneca acquired SixPeaks for a bispecific antibody targeting weight loss while preserving lean muscle mass. Still in early stages, but it signals that the next frontier in obesity pharmacology isn’t just more weight loss—it’s better quality weight loss.

What This Pipeline Means for Patients

The explosion of competition in the GLP-1 space is unequivocally good news for patients, for three reasons.

First, prices will continue to fall. When 16+ competitors are vying for market share, pricing power shifts from manufacturers to patients and insurers. We’re already seeing this with Novo Nordisk and Eli Lilly engaging in unprecedented price cuts.

Second, options for different patient needs are expanding. Some patients need oral medications, some prefer less frequent injections, some prioritize muscle preservation, and some need the absolute maximum weight loss. By 2028, there should be a drug optimized for each of these preferences.

Third, insurance coverage will expand. As more options become available and prices drop, the economic argument against covering obesity medications becomes harder for insurers to sustain. State mandate legislation is already advancing in multiple states, and the IRA Medicare negotiations set a precedent for federal action.